Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Aug 15, 2018 THE NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES TWO ARTICLES ON TROGARZO™ Jul 31, 2018 European Medicines Agency Confirms Accelerated Assessment Procedure for Trogarzo™ Jul 25, 2018 TROGARZO™ INCLUDED IN MOST RECENT TREATMENT GUIDELINES ISSUED BY INTERNATIONAL ANTIVIRAL SOCIETY Jul 05, 2018 Theratechnologies Announces Financial Results for the Second Quarter of 2018 Jul 04, 2018 Theratechnologies Submits Novel Single-Vial Formulation of EGRIFTA® (Tesamorelin for Injection) for FDA Approval Jun 28, 2018 Theratechnologies to Announce Financial Results for Second Quarter 2018 Jun 19, 2018 TH Announces Closing of US$57.5 Million Bought Deal Offering Of 5.75% Convertible Unsecured Senior Notes May 30, 2018 TH and EMD Serono Agree on Early and Final Payment May 30, 2018 TH Announces US$50 Million Bought Deal Offering Of 5.75% Convertible Unsecured Senior Notes May 23, 2018 TH Announces Agreement with AIDS DRUG ASSITANCE PROGRAM (ADAP) for TROGARZO™ and EGRIFTA® First page « Previous page ‹ … Page 22 Page 23 Page 24 Page 25 Current page 26 Page 27 Page 28 Page 29 Page 30 … Next page › Last page » Displaying 251 - 260 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Jul 25, 2018 TROGARZO™ INCLUDED IN MOST RECENT TREATMENT GUIDELINES ISSUED BY INTERNATIONAL ANTIVIRAL SOCIETY
Jul 04, 2018 Theratechnologies Submits Novel Single-Vial Formulation of EGRIFTA® (Tesamorelin for Injection) for FDA Approval
Jun 19, 2018 TH Announces Closing of US$57.5 Million Bought Deal Offering Of 5.75% Convertible Unsecured Senior Notes
May 30, 2018 TH Announces US$50 Million Bought Deal Offering Of 5.75% Convertible Unsecured Senior Notes
May 23, 2018 TH Announces Agreement with AIDS DRUG ASSITANCE PROGRAM (ADAP) for TROGARZO™ and EGRIFTA®
